Show simple item record

dc.contributor.authorBertran, Kateri
dc.contributor.authorKassa, Aemro
dc.contributor.authorCriado, Miria F.
dc.contributor.authorNuñez, Ivette A.
dc.contributor.authorLee, Dong-Hun
dc.contributor.authorKillmaster, Lindsay
dc.contributor.authorSá e Silva, Mariana
dc.contributor.authorRoss, Ted M.
dc.contributor.authorMebatsion, Teshome
dc.contributor.authorPritchard, Nikki
dc.contributor.authorSwayne, David E.
dc.contributor.otherProducció Animalca
dc.date.accessioned2021-03-29T09:01:08Z
dc.date.available2021-03-29T09:01:08Z
dc.date.issued2021-03-11
dc.identifier.citationBertran, Kateri, Aemro Kassa, Miria F. Criado, Ivette A. Nuñez, Dong-Hun Lee, Lindsay Killmaster, and Mariana Sá e Silva et al. 2021. "Efficacy Of Recombinant Marek’S Disease Virus Vectored Vaccines With Computationally Optimized Broadly Reactive Antigen (COBRA) Hemagglutinin Insert Against Genetically Diverse H5 High Pathogenicity Avian Influenza Viruses". Vaccine 39 (14): 1933-1942. doi:10.1016/j.vaccine.2021.02.075.ca
dc.identifier.issn0264-410Xca
dc.identifier.urihttp://hdl.handle.net/20.500.12327/1228
dc.description.abstractThe genetic and antigenic drift associated with the high pathogenicity avian influenza (HPAI) viruses of Goose/Guangdong (Gs/GD) lineage and the emergence of vaccine-resistant field viruses underscores the need for a broadly protective H5 influenza A vaccine. Here, we tested experimental vector herpesvirus of turkey (vHVT)-H5 vaccines containing either wild-type clade 2.3.4.4A-derived H5 inserts or computationally optimized broadly reactive antigen (COBRA) inserts with challenge by homologous and genetically divergent H5 HPAI Gs/GD lineage viruses in chickens. Direct assessment of protection was confirmed for all the tested constructs, which provided clinical protection against the homologous and heterologous H5 HPAI Gs/GD challenge viruses and significantly decreased oropharyngeal shedding titers compared to the sham vaccine. The cross reactivity was assessed by hemagglutinin inhibition (HI) and focus reduction assay against a panel of phylogenetically and antigenically diverse H5 strains. The COBRA-derived H5 inserts elicited antibody responses against antigenically diverse strains, while the wild-type-derived H5 vaccines elicited protection mostly against close antigenically related clades 2.3.4.4A and 2.3.4.4D viruses. In conclusion, the HVT vector, a widely used replicating vaccine platform in poultry, with H5 insert provides clinical protection and significant reduction of viral shedding against homologous and heterologous challenge. In addition, the COBRA-derived inserts have the potential to be used against antigenically distinct co-circulating viruses and future drift variants.ca
dc.format.extent10ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofVaccineca
dc.rightsAttribution 4.0 Internationalca
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleEfficacy of recombinant Marek’s disease virus vectored vaccines with computationally optimized broadly reactive antigen (COBRA) hemagglutinin insert against genetically diverse H5 high pathogenicity avian influenza virusesca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc619ca
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2021.02.075ca
dc.contributor.groupSanitat Animalca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/